Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Andrea Sutton

Nurse Practitioner, Adult Health Birmingham, AL Nurse Practitioner

NPI 1467725267 CMS profile 11127945

48 Medical Park Dr E, Suite 351, Birmingham, AL 35235

Open in the dashboard

General payments

$20,758

324 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Andrea Sutton of Birmingham, AL is reported in the CMS Open Payments database as having received $20,758 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $105 4
2022 General $424 21
2021 General $20,205 298

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Sutton
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Andrea Sutton were reported at $0. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Andrea Sutton Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $20,205 $138 $43–$438 $132
2022 $424 $165 $54–$494 $149
2023 $105 $178 $61–$549 $160
2024 $24 $186 $62–$575 $164
2025 $0 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Biohaven Pharmaceuticals, Inc. $16,155 74 payments
  2. CSL Behring $641 14 payments
  3. AbbVie, Inc. $636 51 payments
  4. Amgen Inc. $446 26 payments
  5. UCB, Inc. $353 21 payments
  6. Novartis Pharmaceuticals Corporation $301 17 payments
  7. Biogen, Inc. $280 14 payments
  8. Acorda Therapeutics, Inc $254 17 payments
  9. Lundbeck LLC $196 9 payments
  10. Adamas Pharmaceuticals, Inc. $172 8 payments
  11. Other $1,325 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,499 28 payments
  2. Food and Beverage $5,771 285 payments
  3. Travel and Lodging $1,480 9 payments
  4. Education $8 2 payments
Products named General payments · program years 2021–2024
  1. NURTEC ODT $16,177 75 payments
  2. Hizentra $641 14 payments
  3. AIMOVIG $535 30 payments
  4. UBRELVY $353 34 payments
  5. INBRIJA $239 16 payments
  6. VUMERITY $224 11 payments
  7. Neupro $205 10 payments
  8. VYEPTI $196 9 payments
  9. KESIMPTA $195 12 payments
  10. MAYZENT $179 11 payments
  11. Other $2,022 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$2,640

Medicare's payments for the services billed

Medicare patients

21

Average age 76

Services billed

37

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Chronic kidney disease 67%
Heart failure 62%
Atrial fibrillation 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $12
$12 — —
BOTOX
  • AbbVie, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record